6-ethoxycarbonyl-8-methoxy-2(1H)-quinolinone | 165592-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-ethoxycarbonyl-8-methoxy-2(1H)-quinolinone
• 英文别名: 8-methoxy-6-ethoxycarbonylcarbostyril；ethyl 8-methoxy-2-oxo-1H-quinoline-6-carboxylate
• CAS: 165592-29-0
• 化学式: C₁₃H₁₃NO₄
• 分子量: 247.251
• InChiKey: CAVYJZAVGVRWPE-UHFFFAOYSA-N

物化性质

• 沸点：
  480.9±45.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-ethoxycarbonyl-8-methoxy-2(1H)-quinolinone 在 钯 silica gel 、 氯仿 、 diethyl ether ; compound with chloroform 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以to obtain 0.85 g of 8-methoxy-6-ethoxycarbonyl-3,4-dihydrocarbostyril as a white powder的产率得到8-methoxy-6-ethoxycarbonyl-3,4-dihydrocarbostyril
  参考文献：
  名称：

  Peripheral vasodilators

  摘要：

  含有周围血管扩张剂的活性成分，其为由以下通式表示的羧基苯基吡喃衍生物或其盐：##STR1##以及在上述通式范围内的新型羧基苯基吡喃衍生物。

  公开号：

  US05591751A1
• 作为产物：
  描述：

  3-甲氧基-4-氨基苯甲酸甲酯 在 盐酸 、 N-氯代丁二酰亚胺 、 sodium hydride 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 18.5h， 生成 6-ethoxycarbonyl-8-methoxy-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o

文献信息

• PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0636128A1

  公开（公告）日：1995-02-01
• US5591751A
  申请人：——

  公开号：US5591751A

  公开（公告）日：1997-01-07
• [EN] PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS<br/>[FR] UTILISATION DE PIPERAZINOCARBONYLCARBOSTYRILES COMME VASODILATATEURS PERIPHERIQUES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：WO1994019339A1

  公开（公告）日：1994-09-01

  (EN) The present invention provides novel peripheral vasodilating agents and novel carbostyril derivatives having peripheral vasodilating activity. Peripheral vasodilating agents containing, as the active ingredient, carbostyril derivatives represented by general formula (1) or salt thereof; and novel carbostyril derivatives which are included within the scope of the above-mentioned general formula.(FR) La présente invention concerne de nouveaux agents de vasodilatation périphérique et de nouveaux dérivés de carbostyrile ayant une activité de vasodilatation périphérique. Agents de vasodilatation périphérique contenant, comme ingrédient actif, des dérivés de carbostyrile représentés par la formule générale (1), ou sel tiré de ces dérivés; et nouveaux dérivés du carbostyrile, inclus dans ladite formule générale.
• Peripheral vasodilators
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05591751A1

  公开（公告）日：1997-01-07

  Peripheral vasodilating agents containing, as the active ingredient, carbostyril derivatives represented by the general formula: ##STR1## or a salt thereof; and novel carbostyril derivatives included within the scope of the above-mentioned general formula.

  含有周围血管扩张剂的药物，活性成分为一般式表示的卡波司烯衍生物，或其盐；以及包含在上述一般式范围内的新型卡波司烯衍生物。
• Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives
  作者：Shuji Teramoto、Michinori Tanaka、Hiroshi Shimizu、Takafumi Fujioka、Fujio Tabusa、Takashi Imaizumi、Kenji Yoshida、Hiroyuki Fujiki、Toyoki Mori、Takumi Sumida、Michiaki Tominaga

  DOI：10.1021/jm020597o

  日期：2003.7.1

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.